Form 4: Tonix Pharmaceuticals CFO Reports Stock Transactions

Bradley Saenger, CFO of Tonix Pharmaceuticals, reports the surrender of shares following a reverse stock split and the grant of stock options.

Summary

• On February 5, 2025, Bradley Saenger, the Chief Financial Officer of Tonix Pharmaceuticals Holding Corp., reported changes in beneficial ownership.
• Saenger surrendered 0.04 shares of common stock following a reverse stock split.
• Saenger was also granted two stock option awards on February 25, 2025, each for 25,792 shares of common stock.
• The options have exercise prices of $8.05 and $10.0625, respectively.
• The options vest over a 36-month period, starting on February 25, 2026, and expire on February 25, 2035.
• The options were granted under the company's Amended and Restated 2020 Stock Incentive Plan.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing, so the sentiment is neutral.

Positives

• The granting of stock options to the CFO aligns his interests with those of the shareholders.
• The vesting schedule of the options encourages long-term commitment from the CFO.

Future Outlook

NA

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. Stock option grants are a common form of executive compensation in the pharmaceutical industry.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the pharmaceutical industry, often used to incentivize performance and align management's interests with those of shareholders.
• Vesting schedules, such as the one described (one-third vesting on the first anniversary and then monthly for 24 months), are standard practice to ensure long-term commitment.
• Comparing the size of the option grants and the exercise prices to those of peer companies like BioNTech, Moderna, or Novavax would provide a better understanding of whether the compensation is in line with industry norms.

Stakeholder Impact

• The stock option grants could potentially dilute existing shareholders if the options are exercised.
• The transactions provide transparency to shareholders regarding insider activity.

Key Dates